19:52 , Feb 23, 2018 |  BioCentury  |  Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
23:05 , Feb 2, 2017 |  BC Innovations  |  Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: K-Ras (KRAS); calmodulin; protein kinase C (PKC)

Cancer INDICATION: Pancreatic cancer Mouse studies suggest inhibiting the KRAS- calmodulin interaction by activating PKC could help treat KRAS-driven pancreatic cancer. In a human pancreatic cell line harboring oncogenic KRAS , the PKC activator prostratin...
07:00 , Mar 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein kinase C (PKC) α (PRKCA); PKC δ (PRKCD); PKC θ (PRKCQ)

Cancer INDICATION: Cancer In vitro studies have identified bryostatin-derived PKC modulators that could help treat cancer and other indications. Chemical synthesis and in vitro testing identified three bryostatin analogs that bound the PKC isoforms α,...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Aphios neurology, ophthalmic news

Aphios said it will spin off a wholly owned subsidiary, Amylon LLC, to develop and commercialize APH-1104 to treat mild to moderate Alzheimer's disease (AD) and other disorders, such as Down's syndrome, Parkinson's disease (PD)...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Aphios, VivaCell deal

The companies partnered to develop and commercialize non-psychotropic cannabinoid drug candidates to treat multiple sclerosis and other CNS neurodegenerative diseases in the U.S. and Europe. The compounds were discovered by phytocannabinoids company VivaCell in collaboration...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Company News

Aphios, Louisiana State University deal

Aphios received exclusive, worldwide rights to the university's IP covering pharmaceutical compositions of bryostatin-1, a modulator of protein kinase C activity. Aphios has an unnamed bryostatin-1 compound in Phase I/II testing for Alzheimer's disease. The...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Company News

Aphios, Boston University Medical Center, NIH cancer news

Aphios and the center received a one-year $260,000 Phase I Small Business Technology Transfer (STTR) grant from NIH's National Cancer Institute to develop APH-M109 to treat hormone-refractory prostate cancer (HRPC). Aphios hopes to submit an...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Company News

Aphios infectious news

Cancer and infectious disease company Aphios formed Amyxa Pharmaceuticals, a subsidiary that will focus on discovering and developing influenza compounds. Amyxa hopes to identify the compounds by screening marine microorganisms and medicinal plants using SuperFluids...
08:00 , Dec 19, 2005 |  BC Week In Review  |  Company News

Aphios, Boston University Medical School deal

Aphios received a license from the university to a vitamin D analog that is in preclinical development to treat prostate cancer. Further terms were not disclosed. Aphios Corp. , Woburn, Mass.   Boston University Medical...